For younger patients with relapsed or refractory AML, the use of decitabine with venetoclax may be an appropriate salvage therapy, and is comparable to intensive chemotherapy regimens.
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.
Encouraging antitumor activity and durable responses were reported with odronextamab among patients with highly refractory B-cell NHLs.
Investigators assessed mortality rates and other outcomes in patients with hematologic malignancies and COVID-19 infection.
Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin may benefit patients with treatment-naive or relapsed/refractory acute myeloid leukemia.
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.